Biomarker
60
14
18
22
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
1.7%
1 terminated out of 60 trials
95.7%
+9.1% vs benchmark
5%
3 trials in Phase 3/4
0%
0 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (60)
Role of aGVHD Biomarkers on aGVHD Risks
The Application of Biomarkers in the Care of Patients With Atrial Fibrillation
Tennessee Alzheimer's Project
Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock
Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor
Novel Biomarkers and Postoperative Kidney Injury in Radical Nephrectomy
Biomarkers to Predict Gain From Therapy in Motor Stroke
Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia
DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis
Study of Peripheral Blood CHI3L1 to Predict Tumor Response to Radiotherapy
Neurobiomarker for Prism Adaptation Treatment Response
S100A8 in Serum and Urine as a New Biomarker in Lupus Nephritis
Role of IL 12 and IL 23 as Potential Biomarkers in Diagnosis of Early Crohn's Disease
Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions
''Comparative Evaluation of Change in Bite Force and Levels of Bone Turnover Markers CTX and BALP in Hyperdivergent and Hypodivergent Cases During Retention Phases-A Prospective Clinical Trial ''
The Correlation Between Ovarian Function and Serum Biomarkers
Serum Calprotectin in Surgical Septic Patients
Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease
The Effects of Smoking on miRNA-223 Before-After Non-Surgical Periodontal Therapy
A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer